Association of tirzepatide versus Glucagon-Like Peptide-1 receptor agonists with oral and periodontal outcomes in patients with type 2 Diabetes: A Global propensity Score–Matched cohort study
Authors' conclusion
Tirzepatide was associated with lower risks of recorded oral and periodontal outcomes than GLP-1RAs.
Study context
- Population
- Adults with T2D receiving tirzepatide or GLP-1 RA between May 2022 and May 2025, TriNetX Global Collaborative Networkmatched cohort
- Participants
- 97,993 vs 97,993
- Exposure
- Tirzepatide vs GLP-1 RA
- Tirzepatiden = 97,993
- GLP-1RAsn = 97,993reference
- Outcome
- Mortality and oral and periodontal outcomes
- Follow-up
- 1-year follow-up
Methodological detailspropensity-score matched, 1:1 matching, TriNetX Global Collaborative Network
- Propensity-score matched
- 1:1 matching
- TriNetX Global Collaborative Network
Main finding
As reported in the abstract
Tirzepatide vs GLP-1RAsHazard ratio (95% CI)
Mortality
0.69(0.59–0.80)
Periodontitis
0.70(0.57–0.86)
Tooth extraction
0.89(0.84–0.94)
Peri-implant complications
0.61(0.52–0.70)
Periodontal procedures
0.89(0.85–0.94)
Oral or maxillofacial infections
0.70(0.62–0.79)
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| Composite oral/periodontal outcome | 0.87 (0.84–0.91) | |
| 0.512Hazard ratio (log scale) |
Additional analyses (subgroup, extended follow-up, active-comparator, E-value)
- Directionally consistent findings across additional analyses
Original publication
Association of tirzepatide versus Glucagon-Like Peptide-1 receptor agonists with oral and periodontal outcomes in patients with type 2 Diabetes: A Global propensity Score–Matched cohort study. Diabetes Res Clin Pract. Published 20 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →